SLC13A3

Na(+)/dicarboxylate cotransporter 3 · Q8WWT9 · SLC13A3 on Sugi Atlas →

1,602 patent compounds predicted against SLC13A3, 1,289 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Alpha-Ketoglutaric Acid (SCHEMBL7400)	1.00	1/20
Alpha-Ketoglutaric Acid (SCHEMBL932116)	1.00	1/20
Alpha-Ketoglutaric Acid (SCHEMBL3776640)	1.00	1/20
Alpha-Ketoglutaric Acid (SCHEMBL1042910)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL1131520)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL1242830)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL1428274)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL1456849)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL2823722)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL2824012)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL2826782)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL3184813)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL3806602)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL4896335)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL4896347)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL6545627)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL8974974)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL9782859)	0.93	1/20
Alpha-Ketoglutaric Acid (SCHEMBL2402805)	0.88	1/20
Alpha-Ketoglutaric Acid (SCHEMBL9121)	0.82	1/20

Clinical trials — most relevant to SLC13A3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder	PHASE1/PHASE2	NOT_YET_RECRUITING
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®	PHASE1/PHASE2	COMPLETED
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
SLC13A5 Deficiency Natural History Study - United States Only	nan	ENROLLING_BY_INVITATION
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Sodium Transport: Genetics and Hypertension	nan	COMPLETED
Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital	nan	UNKNOWN
Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter	nan	COMPLETED
Lithium Countertransport and Blood Pressure In CARDIA and TOMHS	nan	COMPLETED
Effect of SLC01B1 (rs2306283) Polymorphism on the Efficacy and Safety Profile of Atorvastatin in Pakistani Population	nan	COMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Clinical and Laboratory Study of Methylmalonic Acidemia	nan	RECRUITING
Oxalate and Citrate	nan	RECRUITING
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy	nan	COMPLETED
Gyrate Atrophy Ocular and Systemic Study	nan	ACTIVE_NOT_RECRUITING
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
Renal Transporters After Renal Transplantation	nan	UNKNOWN
POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS	nan	NOT_YET_RECRUITING
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA])	nan	COMPLETED
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient	nan	UNKNOWN
Natural History Study of ATP1A3-related Disease	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLC13A3 binder may also engage these)

Protein	Name	Similarity
Q91Y63	—	0.998	Q91Y63 →
Q9Z0Z5	—	0.995	Q9Z0Z5 →
Q9ES88	—	0.982	Q9ES88 →
SLC13A2	Solute carrier family 13 member 2	0.982	landscape →
Q28615	—	0.981	Q28615 →
P70545	—	0.980	P70545 →
Q67BT3	—	0.978	Q67BT3 →
SLC13A5	Na(+)/citrate cotransporter	0.978	landscape →
Q9JHI4	—	0.976	Q9JHI4 →
Q9UKG4	—	0.972	Q9UKG4 →
Q07782	—	0.969	Q07782 →
Q8CJ44	—	0.969	Q8CJ44 →
Q9BZW2	—	0.967	Q9BZW2 →
SLC5A11	Sodium/myo-inositol cotransporter 2	0.956	landscape →
O35921	—	0.953	O35921 →
Q2M3M2	—	0.953	Q2M3M2 →
O00341	—	0.953	O00341 →
Q95JC7	—	0.952	Q95JC7 →
SLC26A3	Chloride anion exchanger	0.951	landscape →
O35544	—	0.951	O35544 →
Q9N1R2	—	0.951	Q9N1R2 →
Q3ZC26	—	0.951	Q3ZC26 →
Q8JZR4	—	0.950	Q8JZR4 →
O35874	—	0.950	O35874 →
A4IHB9	—	0.949	A4IHB9 →
SLC1A1	Excitatory amino acid transporter 3	0.949	landscape →
Q25605	—	0.949	Q25605 →
P24942	—	0.948	P24942 →
Q5SWY8	—	0.948	Q5SWY8 →
Q8VDT1	—	0.948	Q8VDT1 →